Adenocarcinomas News and Research RSS Feed - Adenocarcinomas News and Research

Adenocarcinoma is cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.
Penn research reveals additional pathway for origin of colon cancer

Penn research reveals additional pathway for origin of colon cancer

Cancer researchers already know of some oncogenes and other factors that promote the development of colon cancers, but they don't yet have the full picture of how these cancers originate and spread. Now researchers from the Perelman School of Medicine at the University of Pennsylvania have illuminated another powerful factor in this process. [More]
Intraoperative fluorescent imaging detects lung adenocarcinoma during pulmonary resection

Intraoperative fluorescent imaging detects lung adenocarcinoma during pulmonary resection

More than 80,000 people undergo resection of a pulmonary tumor each year, and currently the only method to determine if the tumor is malignant is histologic analysis. A new study reports that a targeted molecular contrast agent can be used successfully to cause lung adenocarcinomas to fluoresce during pulmonary surgery. [More]
UCLA scientists identify new method to deliver glucose to pancreatic and prostate cancer cells

UCLA scientists identify new method to deliver glucose to pancreatic and prostate cancer cells

UCLA scientists have for the first time identified a new sodium-dependent mechanism to deliver glucose—the body's main fuel that drives tumor growth—to pancreatic and prostate cancer cells, offering new hope in the fight against two of the deadliest forms of the disease. [More]
Some lung cancer patients can benefit from melanoma drugs

Some lung cancer patients can benefit from melanoma drugs

A subset of lung cancer patients can derive important clinical benefits from drugs that are more commonly used to treat melanoma, the authors of a new academic clinical trial in Europe have reported at the European Lung Cancer Conference (ELCC) in Geneva, Switzerland. [More]
apceth begins Agenmestencel-T Phase II clinical trial in gastrointestinal cancer patients

apceth begins Agenmestencel-T Phase II clinical trial in gastrointestinal cancer patients

apceth, a global leader in engineered cell therapies, today announced the successful completion of the Phase I and initiation of the Phase II part of its ongoing monocentric Phase I/II clinical trial TREAT-ME 1 with the engineered cell therapeutic product Agenmestencel-T, at the Klinikum Grosshadern in Munich. [More]
BUSM researchers discover genes involved in formation of lung tumors

BUSM researchers discover genes involved in formation of lung tumors

The lung transcription factor Nkx2-1 is an important gene regulating lung formation and normal respiratory functions after birth. Alterations in the expression of this transcription factor can lead to diseases such as lung interstitial disease, post-natal respiratory distress and lung cancer. [More]
MET amplified in NSCLC irrespective of type, genetic background

MET amplified in NSCLC irrespective of type, genetic background

A third of non-small-cell lung cancers show low- to high-level amplification of the MET gene, according to a German study, with no significant difference in frequency across different types of cancer and genetic backgrounds. [More]
New guidance recommends use of primary HPV test for cervical cancer screening

New guidance recommends use of primary HPV test for cervical cancer screening

About 80 million U.S. women ages 25 to 65 should be screened periodically by their health care providers for cervical cancer. At present, the standard way to do that is a Pap smear alone, or co-testing using both a Pap smear and a human papillomavirus (HPV) test. [More]
Single biopsy site may reveal all lung adenocarcinoma genetic mutations

Single biopsy site may reveal all lung adenocarcinoma genetic mutations

Genetic sequencing of a single tumour site sample may be adequate for identifying cancer gene mutations in patients with lung andenocarcinoma, research published in Science suggests. [More]
CT screening highly sensitive, specific for lung cancer detection

CT screening highly sensitive, specific for lung cancer detection

Low-dose computed tomography screening for lung cancer has high specificity and high sensitivity, with just a small number of interval cancers, finds an interim analysis of the NELSON trial. [More]
Mayo Clinic study finds that chromosomal rearrangements can help trace lineage of lung cancer

Mayo Clinic study finds that chromosomal rearrangements can help trace lineage of lung cancer

A diagnostic test based on chromosomal rearrangements can trace the lineage of lung cancer to determine whether two separate lung cancers in the same patient are independent tumors or a tumor that has spread to another region of the lung, a Mayo Clinic study has found. For patients with multiple tumors, that distinction could mean the difference between early stage cancer that may be cured by surgery and incurable late-stage disease. [More]
Researchers explain interaction between HNRNPA2B1 protein and pancreatic cancer development

Researchers explain interaction between HNRNPA2B1 protein and pancreatic cancer development

Researchers from the University of Barcelona have described an interaction between the protein HNRNPA2B1 and pancreatic cancer development which remained unknown. The study, published in the journal Gastroenterology, has proved in human cancer cell lines that this protein is essential to the correct activity of the oncogenic protein KRAS, related to cancer start and development. [More]
Study addresses the challenge of genomic heterogeneity

Study addresses the challenge of genomic heterogeneity

Known cancer-driving genomic aberrations in localized lung cancer appear to be so consistently present across tumors that a single biopsy of one region of the tumor is likely to identify most of them, according to a paper published today in Science. [More]
XAGE1 antibody confers survival benefits to lung adenocarcinoma patients

XAGE1 antibody confers survival benefits to lung adenocarcinoma patients

Patients with advanced lung adenocarcinoma who produce the XAGE1 antibody appear to survive twice as long as those who do not produce it, Japanese study data show. [More]
OGT to highlight NGS and FISH methods for tumour screening at BSGM 2014

OGT to highlight NGS and FISH methods for tumour screening at BSGM 2014

Oxford Gene Technology, The Molecular Genetics Company, is inviting attendees of the British Society for Genetic Medicine annual conference to its seminar entitled ‘Approaches to tumour screening and therapy stratification: case studies in Non-Small Cell Lung Cancer’ on Monday 22nd September, 13.10-13.50, room 2N. [More]
Scientists analyze genetic characteristics of cancers using multiple genomic technology platforms

Scientists analyze genetic characteristics of cancers using multiple genomic technology platforms

New research partly led by UC San Francisco-affiliated scientists suggests that one in 10 cancer patients would be more accurately diagnosed if their tumors were defined by cellular and molecular criteria rather than by the tissues in which they originated, and that this information, in turn, could lead to more appropriate treatments. [More]
New vaccine reprograms pancreatic tumors and makes them vulnerable to immunotherapy

New vaccine reprograms pancreatic tumors and makes them vulnerable to immunotherapy

Researchers at the Johns Hopkins Kimmel Cancer Center have developed and tested a vaccine that triggered the growth of immune cell nodules within pancreatic tumors, essentially reprogramming these intractable cancers and potentially making them vulnerable to immune-based therapies. [More]
Castle Biosciences reports study results from DecisionDx-EC multi-analyte test for esophageal cancer

Castle Biosciences reports study results from DecisionDx-EC multi-analyte test for esophageal cancer

Castle Biosciences Inc. today announced study results from its proprietary multi-analyte test DecisionDx-EC, which is designed to determine which patients with esophageal cancer are likely to respond or not respond to standard pre-surgical chemoradiation therapy. [More]
Researchers develop new strategy to personalised medicine in advanced cancer patients

Researchers develop new strategy to personalised medicine in advanced cancer patients

Tumour cells can accumulate hundreds or even thousands of DNA mutations which induce the growth and spread of cancer. The number and pattern of mutations differs according to the type of tumour, even among those that are classified as part of the same type of tumours. [More]
Tau Therapeutics presents data of T-type calcium channel inhibitors in treatment of pancreatic cancer

Tau Therapeutics presents data of T-type calcium channel inhibitors in treatment of pancreatic cancer

Tau Therapeutics LLC announced today that its academic collaborator, University of Virginia Professor Todd Bauer, MD, presented data at the 105th Annual Meeting of the American Association for Cancer Research (AACR), the premier cancer research event held in San Diego, California from April 5-9. [More]
Advertisement